ConductScience.org, home

Paper41584508

Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.

Abbas M and 3 others. EXCLI J, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives. Papers, record 41584508. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41584508

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.
PubMed
Journal
EXCLI J
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-09-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abbas MMateen
2Ali Sami SHSyed Hassam
3Gajdács MMárió
4Tariq MJMuhammad Junaid

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References113

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127226731Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma.Onco Targets Ther2016https://conductscience.org/library/papers/27226731PubMed
228860885Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.Lung Cancer (Auckl)2017https://conductscience.org/library/papers/28860885PubMed
339497711A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement.Front Oncol2024https://conductscience.org/library/papers/39497711PubMed
439083791Examining the Effectiveness of Electronic Patient-Reported Outcomes in People With Cancer: Systematic Review and Meta-Analysis.J Med Internet Res2024https://conductscience.org/library/papers/39083791PubMed
536924668Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.Eur J Med Chem2023https://conductscience.org/library/papers/36924668PubMed
636795308Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors.Curr Cardiol Rep2023https://conductscience.org/library/papers/36795308PubMed
738493021Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.Gynecol Oncol2024https://conductscience.org/library/papers/38493021PubMed
840030100HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.J Clin Oncol2025https://conductscience.org/library/papers/40030100PubMed
935390258Unraveling the Roles of Protein Kinases in Autophagy: An Update on Small-Molecule Compounds for Targeted Therapy.J Med Chem2022https://conductscience.org/library/papers/35390258PubMed
1012006504Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.Clin Cancer Res2002https://conductscience.org/library/papers/12006504PubMed
1139840079Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa.Front Pharmacol2024https://conductscience.org/library/papers/39840079PubMed
1235900722Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.Ther Innov Regul Sci2022https://conductscience.org/library/papers/35900722PubMed
1338101437
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Lancet Respir Med2024https://conductscience.org/library/papers/38101437PubMed
1438788184Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer-A Practical Guide.Am Soc Clin Oncol Educ Book2024https://conductscience.org/library/papers/38788184PubMed
1523730014Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.Indian J Hematol Blood Transfus2012https://conductscience.org/library/papers/23730014PubMed
1638870746The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project.Eur J Cancer2024https://conductscience.org/library/papers/38870746PubMed
1739417568Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.Cancer Control2024https://conductscience.org/library/papers/39417568PubMed
1839248702Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.Cancer Discov2025https://conductscience.org/library/papers/39248702PubMed
1939281823Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.Med Drug Discov2024https://conductscience.org/library/papers/39281823PubMed
2038347575Unveiling the mechanisms and challenges of cancer drug resistance.Cell Commun Signal2024https://conductscience.org/library/papers/38347575PubMed

See all 113 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42749439Molecular study of KIT gene that is related to drug resistance in chronic myeloid leukemia patients.J Genet Eng Biotechnol2026https://conductscience.org/library/papers/42749439PubMed
42496289FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel)2026https://conductscience.org/library/papers/42496289PubMed
42371091From data mining to mechanistic prediction: a study on drug-induced lung injury integrating FAERS, machine learning, and network toxicology.Arch Toxicol2026https://conductscience.org/library/papers/42371091PubMed
42224282Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach.PLoS One2026https://conductscience.org/library/papers/42224282PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41584508

GET https://conductscience.org/api/papers/v1/41584508/references?page=2